CURE’s ovarian cancer page is a go-to resource for oncology news and updates in the world of ovarian cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in ovarian cancer.
June 15th 2020
The combination of mirvetuximab soravtansine and Avastin (bevacizumab) demonstrated encouraging overall response rates in patients with ovarian cancer, regardless of the disease’s previous responsiveness to platinum-based chemotherapy, according to data presented at the 2020 ASCO Virtual Scientific Program.
June 11th 2020
The presentation of the complete data from the NRG-GY004 trial comes just months after AstraZeneca and Merck announced in a press release that the combination failed to meet its primary endpoint of progression-free survival.
June 2nd 2020
Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for May 2020.
May 23rd 2020
One survivor makes the most of the time in the infusion chair, creating beaded jewelry and helping herself and others to heal.
May 21st 2020
In this episode of the “CURE Talks Cancer” podcast, we spoke with a cervical cancer survivor - who is currently living with ovarian cancer - about a cross-country journey she took last summer on a teal and white Harley Davidson motorcycle to raise ovarian cancer awareness.
May 21st 2020
The Food and Drug Administration recently approved the combination of Lynparza (olaparib) and Avastin (bevacizumab) for patients with advanced ovarian cancer that carries a specific mutation and has responded to previous treatment with platinum-based chemotherapy plus Avastin. Here’s what you need to know.
May 20th 2020
The Food and Drug Administration’s recent approval of Zejula is different from previous approvals as it is indicated for all patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, according to a gynecologic oncology expert.
May 14th 2020
Treatment with Lynparza in the maintenance setting extended overall survival by more than a year in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations.
May 8th 2020
Lynparza and Avastin are now approved for patients with advanced ovarian cancer that carries a specific mutation and has responded to previous treatment with platinum-based chemotherapy plus Avastin.
April 29th 2020
The Food and Drug Administration has approved the use of Zejula as a frontline maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who responded to chemotherapy.
April 16th 2020
The COVID-19 pandemic has changed how people receive health care services. For Donna Wiegle, director of the Mill Pond Health Center in Maine, and cervical cancer survivor and patient with ovarian cancer, the pandemic hasn’t yet changed how her island’s health center provides residents with routine care.
April 14th 2020
A two-time survivor shares how taking action led her doctors to catch an aggressive second cancer.
April 13th 2020
After failing to meet its primary endpoint of progression-free survival, the JAVELIN Ovarian PARP 100 clinical trial was stopped.
April 10th 2020
CURE®’s Editor-in-Chief weighs in on how the treatment and detection landscape needs to be refined to help patients with ovarian cancer.
April 9th 2020
An expert raises her concerns about direct-to-consumer testing and shares ways people can protect themselves.
April 8th 2020
Regardless of breastfeeding duration, women who did so after giving birth had a lower risk of developing ovarian cancer, including high-grade tumors.
April 6th 2020
Women with ovarian cancer are living longer than ever, even those whose disease returns after initial treatment.
April 4th 2020
PARP inhibitors show promise in lengthening the life of women with breast cancer, and they're willing to bear the side effects of the treatment.
April 2nd 2020
These targeted therapies fight disease by stopping the fix-it process in damaged cancer cells.
February 18th 2020
PARP Inhibitors are opening new doors in cancer treatment by targeting vulnerabilities in cancer that researchers are beginning to understand better.
February 14th 2020
PARP inhibitors interfere with cancer’s ability to repair damage to its DNA. They are becoming increasingly useful in treating ovarian cancer.
February 5th 2020
Investigators are studying a rare ovarian tumor called sclerosing stromal tumor, a benign tumor that can be misdiagnosed as cancer.
February 2nd 2020
Take a look back at the top five CURE® stories for January 2020.
January 31st 2020
From NFL Hall of Famer Kurt Warner leading a recognition service for cancer caregivers during the Super Bowl to Tylenol’s key ingredient possibly being added to California’s proposition 65 list for chemicals that may cause cancer, here’s what is making headlines in the cancer space this week.